Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Aug;36(2):139P–182P. doi: 10.1111/j.1365-2125.1993.tb04214.x

Proceedings of the British Pharmacological Society. Clinical Pharmacology Section. 14-16 April 1993. Abstracts.

PMCID: PMC1364582  PMID: 8398587

Full text

PDF
139P

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel S. M., Maggs J. L., Back D. J., Park B. K. Cortisol metabolism by human liver in vitro--I. Metabolite identification and inter-individual variability. J Steroid Biochem Mol Biol. 1992 Dec;43(7):713–719. doi: 10.1016/0960-0760(92)90297-v. [DOI] [PubMed] [Google Scholar]
  2. Back D. J., Tjia J. F. Single dose primaquine has no effect on paracetamol clearance. Eur J Clin Pharmacol. 1987;32(2):203–205. doi: 10.1007/BF00542197. [DOI] [PubMed] [Google Scholar]
  3. Bennett E. D., Barclay S. A., Davis A. L., Mannering D., Mehta N. Ascending aortic blood velocity and acceleration using Doppler ultrasound in the assessment of left ventricular function. Cardiovasc Res. 1984 Oct;18(10):632–638. doi: 10.1093/cvr/18.10.632. [DOI] [PubMed] [Google Scholar]
  4. Bond J. H., Jr, Levitt M. D., Prentiss R. Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J Lab Clin Med. 1975 Apr;85(4):546–555. [PubMed] [Google Scholar]
  5. Bornheim L. M., Correia M. A. Selective inactivation of mouse liver cytochrome P-450IIIA by cannabidiol. Mol Pharmacol. 1990 Sep;38(3):319–326. [PubMed] [Google Scholar]
  6. Cholerton S., Idle M. E., Vas A., Gonzalez F. J., Idle J. R. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatogr. 1992 Mar 27;575(2):325–330. doi: 10.1016/0378-4347(92)80166-n. [DOI] [PubMed] [Google Scholar]
  7. Cohn J. N., Archibald D. G., Ziesche S., Franciosa J. A., Harston W. E., Tristani F. E., Dunkman W. B., Jacobs W., Francis G. S., Flohr K. H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. doi: 10.1056/NEJM198606123142404. [DOI] [PubMed] [Google Scholar]
  8. Cook P. R., Brazell I. A. Conformational constraints in nuclear DNA. J Cell Sci. 1976 Nov;22(2):287–302. doi: 10.1242/jcs.22.2.287. [DOI] [PubMed] [Google Scholar]
  9. Corcoran J. S., Owens C. W., Yudkin J. S. Measurement of fingertip blood flow using thermal clearance reflects anastomotic rather than nutrient blood flow. Clin Sci (Lond) 1987 Feb;72(2):225–232. doi: 10.1042/cs0720225. [DOI] [PubMed] [Google Scholar]
  10. Corcos L. Phenobarbital and dexamethasone induce expression of cytochrome P-450 genes from subfamilies IIB, IIC, and IIIA in mouse liver. Drug Metab Dispos. 1992 Nov-Dec;20(6):797–801. [PubMed] [Google Scholar]
  11. Curran R. D., Ferrari F. K., Kispert P. H., Stadler J., Stuehr D. J., Simmons R. L., Billiar T. R. Nitric oxide and nitric oxide-generating compounds inhibit hepatocyte protein synthesis. FASEB J. 1991 Apr;5(7):2085–2092. doi: 10.1096/fasebj.5.7.1707021. [DOI] [PubMed] [Google Scholar]
  12. Daujat M., Pichard L., Fabre I., Pineau T., Fabre G., Bonfils C., Maurel P. Induction protocols for cytochromes P450IIIA in vivo and in primary cultures of animal and human hepatocytes. Methods Enzymol. 1991;206:345–353. doi: 10.1016/0076-6879(91)06104-b. [DOI] [PubMed] [Google Scholar]
  13. Davies B. I., Maesen F. P. Drug interactions with quinolones. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1083–S1090. doi: 10.1093/clinids/11.supplement_5.s1083. [DOI] [PubMed] [Google Scholar]
  14. Duncan J. N., Parton T., Enos T. Metabolism of aminotetralin analogues in vivo and by rat hepatocytes. Biochem Soc Trans. 1990 Dec;18(6):1200–1201. doi: 10.1042/bst0181200. [DOI] [PubMed] [Google Scholar]
  15. Ellis S. W., Ching M. S., Watson P. F., Henderson C. J., Simula A. P., Lennard M. S., Tucker G. T., Woods H. F. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem Pharmacol. 1992 Aug 18;44(4):617–620. doi: 10.1016/0006-2952(92)90394-x. [DOI] [PubMed] [Google Scholar]
  16. Ellis S. W., Ching M. S., Watson P. F., Henderson C. J., Simula A. P., Lennard M. S., Tucker G. T., Woods H. F. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem Pharmacol. 1992 Aug 18;44(4):617–620. doi: 10.1016/0006-2952(92)90394-x. [DOI] [PubMed] [Google Scholar]
  17. Fernandes M. H., Pestana M., Soares-da-Silva P. Deamination of newly-formed dopamine in rat renal tissues. Br J Pharmacol. 1991 Mar;102(3):778–782. doi: 10.1111/j.1476-5381.1991.tb12250.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fernandes M. H., Soares-da-Silva P. Effects of MAO-A and MAO-B selective inhibitors Ro 41-1049 and Ro 19-6327 on the deamination of newly formed dopamine in the rat kidney. J Pharmacol Exp Ther. 1990 Dec;255(3):1309–1313. [PubMed] [Google Scholar]
  19. Fernandes M. H., Soares-da-Silva P. Type A and B monoamine oxidase activities in the human and rat kidney. Acta Physiol Scand. 1992 Aug;145(4):363–367. doi: 10.1111/j.1748-1716.1992.tb09376.x. [DOI] [PubMed] [Google Scholar]
  20. Fernandes M. H., Soares-da-Silva P. Type A and B monoamine oxidase activities in the human and rat kidney. Acta Physiol Scand. 1992 Aug;145(4):363–367. doi: 10.1111/j.1748-1716.1992.tb09376.x. [DOI] [PubMed] [Google Scholar]
  21. Gardiner S. M., Compton A. M., Bennett T., Palmer R. M., Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension. 1990 May;15(5):486–492. doi: 10.1161/01.hyp.15.5.486. [DOI] [PubMed] [Google Scholar]
  22. Garvey G., Jappy B., Stewart D., Williams A., Duffus P. R., Maitland J. M., Valentine M. J., Wedderburn S., Webster J., Petrie J. C. Grampian Health Board's joint drug formulary. BMJ. 1990 Oct 13;301(6756):851–852. doi: 10.1136/bmj.301.6756.851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Holti G., Mitchell K. W. Estimation of the nutrient skin blood flow using a segmented thermal clearance probe. Clin Exp Dermatol. 1978 Jun;3(2):189–198. doi: 10.1111/j.1365-2230.1978.tb01483.x. [DOI] [PubMed] [Google Scholar]
  24. Jonkman J. H. Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 2):736–742. doi: 10.1016/0091-6749(86)90054-0. [DOI] [PubMed] [Google Scholar]
  25. Leakey T. E. Simultaneous analysis of theophylline, caffeine and eight of their metabolic products in human plasma by gradient high-performance liquid chromatography. J Chromatogr. 1990 May 16;507:199–220. doi: 10.1016/s0021-9673(01)84196-0. [DOI] [PubMed] [Google Scholar]
  26. Leu R. W., Leu N. R., Shannon B. J., Fast D. J. IFN-gamma differentially modulates the susceptibility of L1210 and P815 tumor targets for macrophage-mediated cytotoxicity. Role of macrophage-target interaction coupled to nitric oxide generation, but independent of tumor necrosis factor production. J Immunol. 1991 Sep 15;147(6):1816–1822. [PubMed] [Google Scholar]
  27. Lin L. Y., Kumagai Y., Cho A. K. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem Res Toxicol. 1992 May-Jun;5(3):401–406. doi: 10.1021/tx00027a013. [DOI] [PubMed] [Google Scholar]
  28. Maliepaard M., de Mol N. J., Janssen L. H., van der Neut W., Verboom W., Reinhoudt D. N. Role of lipophilicity in the in vitro antitumour activity of a series of new mitosene compounds. Anticancer Drug Des. 1992 Oct;7(5):415–425. [PubMed] [Google Scholar]
  29. Manara L., Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol. 1985;25:249–273. doi: 10.1146/annurev.pa.25.040185.001341. [DOI] [PubMed] [Google Scholar]
  30. Milton K. A., Ward S. A., Edwards G. Determination of halofantrine and its principal metabolite desbutylhalofantrine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr. 1988 Dec 9;433:339–344. doi: 10.1016/s0378-4347(00)80618-0. [DOI] [PubMed] [Google Scholar]
  31. Moldéus P., Ross D., Larsson R. Co-oxidation of xenobiotics. Biochem Soc Trans. 1985 Oct;13(5):847–850. doi: 10.1042/bst0130847. [DOI] [PubMed] [Google Scholar]
  32. Motwani J. G., Fenwick M. K., Morton J. J., Struthers A. D. Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation. 1992 Aug;86(2):439–445. doi: 10.1161/01.cir.86.2.439. [DOI] [PubMed] [Google Scholar]
  33. Otton S. V., Crewe H. K., Lennard M. S., Tucker G. T., Woods H. F. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988 Oct;247(1):242–247. [PubMed] [Google Scholar]
  35. RUTTAN H. R., WRONG N. M. The leprosy problem in Canada with report of a case. Can Med Assoc J. 1958 Jan 1;78(1):19–21. [PMC free article] [PubMed] [Google Scholar]
  36. Rautio A., Kraul H., Kojo A., Salmela E., Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics. 1992 Oct;2(5):227–233. doi: 10.1097/00008571-199210000-00005. [DOI] [PubMed] [Google Scholar]
  37. Rees D. D., Palmer R. M., Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989 May;86(9):3375–3378. doi: 10.1073/pnas.86.9.3375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Reinerink E. J., Doorn L., Jansen E. H., Van Iersel A. A. Measurement of enzyme activities of cytochrome P-450 isoenzymes by high-performance liquid chromatographic analysis of products. J Chromatogr. 1991 Aug 16;553(1-2):233–241. doi: 10.1016/s0021-9673(01)88493-4. [DOI] [PubMed] [Google Scholar]
  39. Richards A. M., Rao G., Espiner E. A., Yandle T. Interaction of angiotensin converting enzyme inhibition and atrial natriuretic factor. Hypertension. 1989 Mar;13(3):193–199. doi: 10.1161/01.hyp.13.3.193. [DOI] [PubMed] [Google Scholar]
  40. Seidegård J., DePierre J. W., Pero R. W. Measurement and characterization of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood. Cancer Res. 1984 Sep;44(9):3654–3660. [PubMed] [Google Scholar]
  41. Smith D. A., Jones B. C. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992 Dec 1;44(11):2089–2098. doi: 10.1016/0006-2952(92)90333-e. [DOI] [PubMed] [Google Scholar]
  42. So E. L., Penry J. K. Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. Epilepsia. 1981 Aug;22(4):467–473. doi: 10.1111/j.1528-1157.1981.tb06157.x. [DOI] [PubMed] [Google Scholar]
  43. Spielberg S. P. Acetaminophen toxicity in human lymphocytes in vitro. J Pharmacol Exp Ther. 1980 May;213(2):395–398. [PubMed] [Google Scholar]
  44. Statland B. E., Demas T., Danis M. Letter: Caffeine accumulation associated with alcoholic liver disease. N Engl J Med. 1976 Jul 8;295(2):110–111. [PubMed] [Google Scholar]
  45. Tanaka E., Ishikawa A., Yamamoto Y., Uchida E., Kobayashi S., Yasuhara H., Misawa S. Simplified approach for evaluation of hepatic drug-oxidizing capacity with a simultaneous measurement of caffeine and its primary demethylated metabolites in carbon tetrachloride-intoxicated rats. Xenobiotica. 1992 May;22(5):535–541. doi: 10.3109/00498259209053116. [DOI] [PubMed] [Google Scholar]
  46. Vermeulen N. P., Bessems J. G., Van de Straat R. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. Drug Metab Rev. 1992;24(3):367–407. doi: 10.3109/03602539208996298. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES